Stockscreener 앱 받기
4.32
1.14%
-0.05
시간 외 거래:
4.32
Aclaris Therapeutics Inc 주식(ACRS)의 최신 뉴스
Aclaris Therapeutics (ACRS) Gains Analyst Attention as Stifel Flags Penny Stock OpportunityEarnings Revision Report - newsline.com
Aclaris (ACRS) director Andrew Schiff reports RSU vesting and new stock option grant - Stock Titan
Aclaris Therapeutics (ACRS) director gains new RSUs and stock options - Stock Titan
Stifel Raises Aclaris Therapeutics Price Target to Four Dollars - HarianBasis.co
Aclaris Therapeutics, Inc. (ACRS): A Top Penny Stock in Investors Portfolio That Stifel is Bullish On - Insider Monkey
Aclaris Therapeutics maps busy pipeline calendar, plans phase 2 asthma trial for ATI-052 - MSN
Aclaris Stockholders Approve Directors, Pay and Auditor - TipRanks
Shareholders at Aclaris (NASDAQ: ACRS) back directors, executive pay and PwC - Stock Titan
Aclaris Therapeutics Maps Busy Pipeline Calendar, Plans Phase 2 Asthma Trial for ATI-052 - Yahoo Finance
ACRS: All proposals passed, with no stockholder questions submitted during the meeting - TradingView
Q2 Earnings Forecast for ACRS Issued By Lifesci Capital - MarketBeat
This Piper Sandler Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations From Tuesday - Benzinga
Aclaris Therapeutics Price Target Announced at $13.00/Share by LifeSci Capital - Moomoo
ACRS Initiated Coverage by LifeSci Capital -- Rating 'Outperform' - GuruFocus
Aclaris Dips Ahead of Jefferies, With Focus on 2026 Trial Data - Bez Kabli
Aclaris Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference - Investing News Network
Aclaris Therapeutics (ACRS) Edges Higher, Testing Key Resistance Near $4.81High Conviction Picks - The Legal Advocate
Aclaris Therapeutics (ACRS) Edges Higher, Testing Resistance After Modest UptickGrowth ETF - The Legal Advocate
Aclaris Therapeutics Holds Steady Near Mid-Range as Traders Eye Key Support and ResistanceVolume Climax - thelegaladvocate.com
Aclaris Therapeutics (ACRS) Edges Lower Amid Tight Trading RangeHigh Conviction Picks - The Legal Advocate
Aclaris Therapeutics (ACRS) Holds Near Support as Volume Suggests Cautious SentimentCTA Positioning - The Legal Advocate
Aclaris Therapeutics, Inc. Stock 12‑Month Price Target Raised to $10.2, Implies 126% Upside - TradingView
926-share sale notice for Aclaris Therapeutics (NASDAQ: ACLS) via Form 144 - Stock Titan
Aclaris Therapeutics (ACRS) price target increased by 12.65% to 9.64 - MSN
Aclaris Therapeutics, Inc.Common Stock (NQ: ACRS - The Chronicle-Journal
Aclaris Expands Immunology Pipeline Ahead of Key Trial Data - MyChesCo
ACRS: Multiple late-stage immunology assets advance toward key 2024 milestones, backed by robust funding - TradingView
ACRS: Multiple innovative I&I therapies advance toward key Phase 2b milestones in 2026 - TradingView
Aclaris (ACRS) Crushes Q1 2026 Estimates — EPS $-0.15 Tops ViewsSurprise Factor Analysis - newsline.com
Aclaris Therapeutics (ACRS) Reports Q3 Loss, Tops Revenue Estimates - MSN
MSN Money - MSN
H.C. Wainwright Maintains Aclaris Therapeutics(ACRS.US) With Buy Rating, Maintains Target Price $16 - Moomoo
Piper Sandler Maintains Aclaris Therapeutics(ACRS.US) With Buy Rating, Maintains Target Price $11 - Moomoo
Guggenheim Maintains Aclaris Therapeutics(ACRS.US) With Buy Rating, Maintains Target Price $12 - Moomoo
Oppenheimer Maintains Aclaris Therapeutics(ACRS.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Stifel raises Aclaris Therapeutics price target to $4 on pipeline By Investing.com - Investing.com Nigeria
Stifel raises Aclaris Therapeutics price target to $4 on pipeline - Investing.com
Aclaris Therapeutics to Participate in the 2026 Bank of America Healthcare Conference - The Manila Times
Aclaris: Q1 Earnings Snapshot - theheraldreview.com
Aclaris Therapeutics (NASDAQ: ACRS) deepens loss while boosting R&D - Stock Titan
Aclaris Therapeutics Releases Q1 2026 Financial Results - AlphaStreet
Aclaris Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate and Clinical Update - Investing News Network
Craig-Hallum Maintains Aclaris Therapeutics(ACRS.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Aclaris Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Aclaris Therapeutics (ACRS) Reports Q1 Loss, Beats Revenue Estimates - Yahoo Finance
Aclaris Therapeutics | 8-K: Aclaris Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate and Clinical Update - Moomoo
Aclaris (NASDAQ: ACRS) posts Q1 2026 loss but boosts cash runway - Stock Titan
1.04%
0.76%
자본화:
|
볼륨(24시간):